0.8199
price down icon26.79%   -0.3001
pre-market  Vorhandelsmarkt:  .74   -0.0799   -9.75%
loading
Schlusskurs vom Vortag:
$1.12
Offen:
$1.02
24-Stunden-Volumen:
14.49M
Relative Volume:
2.34
Marktkapitalisierung:
$26.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-563.30K
KGV:
-4.1077
EPS:
-0.1996
Netto-Cashflow:
$-22.23M
1W Leistung:
+86.34%
1M Leistung:
+63.98%
6M Leistung:
-12.16%
1J Leistung:
-57.52%
1-Tages-Spanne:
Value
$0.77
$1.03
1-Wochen-Bereich:
Value
$0.4011
$1.59
52-Wochen-Spanne:
Value
$0.38
$2.1168

Promis Neurosciences Inc Stock (PMN) Company Profile

Name
Firmenname
Promis Neurosciences Inc
Name
Telefon
416-847-6898
Name
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
PMN's Discussions on Twitter

Vergleichen Sie PMN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PMN
Promis Neurosciences Inc
0.8199 14.38M 0 -563.30K -22.23M -0.1996
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten

pulisher
12:09 PM

Is ProMIS Neurosciences Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com

12:09 PM
pulisher
Jul 22, 2025

Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize

Jul 22, 2025
pulisher
Jul 22, 2025

Still undervalued? ProMIS Neurosciences keeps $9.50 target price at Leede - Cantech Letter

Jul 22, 2025
pulisher
Jul 22, 2025

Alzheimer’s stock triples after FDA Fast-Track Designation - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Plunges 24.56% Intraday—Is the FDA Fast Track Outpacing Investor Sentiment? - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Plunges 30.5% Intraday—What Storm Clouds Loom Over a Biotech Betting on Alzheimer’s Innovation? - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

What makes ProMIS Neurosciences Inc. stock price move sharplyBreakout Level Watch - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces Private Placement Financing - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences announces $0.8M registered direct offering - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences announces private placement financing - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences stock gets FDA Fast Track designation for PMN310 - Investing.com

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences (PMN) Secures Funding to Enhance Therapeuti - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

What drives ProMIS Neurosciences Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces Private Placement Financing | PMN Stock News - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Announces $2.4 Million PIPE Financing for Clinical Development of PMN310 - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Drops 9.82% Amid ICICI Bank's Strong Earnings - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Gains FDA Fast Track for PMN310 - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Secures $9.2M Funding Boost: Accelerates Novel Alzheimer's Treatment Development - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Alzheimer's Treatment Pioneer ProMIS Secures New Funding to Accelerate PMN310 Clinical Trials - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310 - Investing.com Australia

Jul 22, 2025
pulisher
Jul 22, 2025

3 Penny Stocks to Watch Now, 7/22/25 - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about ProMIS Neurosciences Inc. stockExceptional return forecasts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ProMIS Neurosciences Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Inc Inc. (PMN) Price Performance: The Role of Supply and Demand - investchronicle.com

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences shares surge 149.77% intraday after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Alzheimer’s stock triples after FDA Fast-Track Designation | 2025-07-21 | Investing News - Stockhouse

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Soars 134%—What’s Fueling This Biotech Breakout? - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences (PMN) up more than 300% since Jul 8 - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Promis Neurosciences shares surge 250% intraday after FDA grants Fast Track designation for PMN310 Alzheimer's treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences: Stock Surge Insight - StocksToTrade

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Soars 157% on FDA Fast Track Designation – What’s Fueling This Volatile Rally? - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Surges: Analyzing Recent Moves - timothysykes.com

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today? - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences shares surge 17.50% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences stock soars after FDA grants Fast Track for Alzheimer’s drug - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Why ProMIS Is Rising In Pre-market? - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug - Investing.com Australia

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences granted Fast Track designation by FDA for PMN310 - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

ProMIS Neurosciences Granted Fast Track Designation by U.S. - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

FDA Fast-Tracks Revolutionary Alzheimer's Drug Promising Fewer Side Effects Than Current Treatments - Stock Titan

Jul 21, 2025

Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):